International Plasma Protein Congress

Keynote address
Martin Seychell, EU Commission, Deputy Director General, DG SANTE   (TBC)

Miguel-Angel Vesga Carasa, Director General — Basque Transfusion Center, Spain  (TBC)

Matthew Hotchko, President — The Marketing Research Bureau

Nizar Mahlaoui, Pediatrician — Necker University Hospital for Children with Rare Disease, Paris (TBC)

Marie-Laure Hecquet, Head of the HealthCare Section — European Directorate for the Quality of Medicines & Healthcare (EDQM - Council of Europe), Department of Biological Standardisation (TBC)

Jose Drabwell, President — International Patient Organisation for Primary Immunodeficiencies (IPOPI)

Stefaan van der Spiegel, Head of Sector, Substances of Human Origin — DG for Health and Food Safety (SANTE), European Commission

Martina Brix-Zuleger, Commissioner, Department VIII/C/1 Blood, Tissues and Cells — Austrian Ministry of Health   (TBC)

Matthias Gessner, Chair European Plasma Alliance, Head Takeda BioLife Plasma Europe Operations

Dagmar Dörmann — German Ministry of Health, Unit 113, Blood and Blood Products, Sera, Vaccines and Tissues (TBC)

Franz Weinauer, Managing Director, Blood Collection Service — Bavarian Red Cross (TBC)

Andrea Maier-Neuner, General Manager — dsai (Deutsche Selbsthilfe angeborene Immundefekte) [German PID patient group] (TBC)

Svenja Tatjana Barckhausen, Senior Director, Plasma Alliance Operations and Protein Procurement — Biotest

Lieven Annemans, Senior Professor in Health Economics — Ghent University

Philippe Van Wilder, Professor in health economics and HTA — Ecole de Santé Publique — Université Libre de Bruxelles

Martine Pergent, President — IPOPI

Adrian Górecki, President & Founder — EDUinstitute.org

Marianna Cavazza — University Bocconi, Italy (TBC)

Tomasz Kluszczynski, Consultant — Vintura

Maarten Van Baelen, Executive Director Europe — PPTA

Tobias Becker — IGH (Interessengeinschaft Hämophiler) (TBC)

Marion Wilkens, President — Alpha1 Deutschland (TBC)

Birgit Schlennert, General Manager — dsai [German PID patient group] (TBC)

Christine Keipert, Head of the Office of the German Hemophilia Registry, Section Coagulation Products — Paul-Ehrlich-Institut (PEI) (TBC)

Volker Wahn, Senior Consultant, Department of Pediatrics — Charité, Berlin (TBC)

Alessandro Gringeri, Chief Medical and R&D Officer — Kedrion (TBC)

Welcome
Oliver Schmitt, Chair, PPTA European Board of Directors; General Manager — CSL Behring (TBC)

Keynote address
François-Xavier Lery, Coordinator for Technologies, Standards and Norms — World Health Organization (TBC)

Research and innovation in the EU — Set-up and possible links to blood and blood components
Stefaan van der Spiegel, Head of Sector, Substances of Human Origin — DG for Health and Food Safety (SANTE), European Commission

The untapped potential of plasma-derived proteins   (Sponsored presentation)
Bagirath Gangadharan, Head of Translational Research — Takeda (TBC)
Andreas Liebminger, Head of Pharmaceutical Sciences and Devices — Takeda  (TBC)

Technical innovations for large-scale plasma processing     (Sponsored presentation)
Dieter Fassnacht — Senior Director — Grifols Process Engineering  (TBC)

Innovation in Primary Immune Deficiencies: The vision of patients
Andrea Gressani, Vice President — Associazone Immunodeficienze Primitive (TBC)

Worldwide Initiative for Rh Disease Eradication: WIRhE
Giuseppe Buonocore, Professor and Chairman of Paediatrics and Neonatology — University of Siena (TBC)

Hyperimmunoglobulins: A European dilemma from a German perspective
Uta Buckpesch-Heberer, Senior Clinical Assessor, Polyclonal and Monoclonal Antibodies — Paul-Ehrlich-Institut (PEI) (TBC)

Specific Immune Globulins to Prevent or Treat Infectious Diseases: Manufacturing Considerations and Challenges
Dorothy Scott, Supervisory Medical Officer & Chief, Plasma Derivatives Branch, Division of Plasma Protein Therapeutics, OTAT — U.S. Food and Drug Administration (TBC)

Hyperimmunes in Europe: Perspectives from a North American Hyperimmune manufacturer
Angela Dyer, Vice President, Regulatory Affairs — Emergent BioSolutions Canada (TBC)

Emerging viruses, and hyperimmune plasma products for prevention and treatment of infectious diseases
Thomas R. Kreil, Associate Professor of Virology; Vice President, Global Pathogen Safety — Takeda (TBC)